NCT00268242 - Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

July 31, 2011

Conditions

Leukemia

Interventions

DRUG

Gemcitabine Hydrochloride

10 mg/m2/ min IV for 12 hours

DRUG

Mitoxantrone Hydrochloride

12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3

Trial Locations (2)

Duke Comprehensive Cancer Center, Durham

Cleveland Clinic Taussig Cancer Center, Cleveland